Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Annoroad Gene Technology Files Hong Kong IPO Prospectus to Capitalize on China’s Molecular Diagnostics Growth

Fineline Cube Apr 16, 2026
Company Deals

Ty Biotech and Shenzhen University Launch Joint Institute for Chlamydomonas-Based Biopharmaceutical Development with $73 Million Investment

Fineline Cube Apr 16, 2026
Company Deals

Insilico Medicine and Ancestor Cell Forge AI-Stem Cell Alliance to Accelerate Exosome Therapeutics Development

Fineline Cube Apr 16, 2026
Company Deals

GSK Acquires 35Pharma for $950 Million to Secure Best-in-Class Pulmonary Arterial Hypertension Therapy HS235

Fineline Cube Apr 16, 2026
Company Deals

Shionogi Launches Corporate Venture Capital Initiative with Strategic Investment in Ophthalmology Startup Restore Vision

Fineline Cube Apr 16, 2026
Policy / Regulatory

China’s State Council Unveils Comprehensive Drug Pricing Reforms to Strengthen Market-Oriented Mechanisms and Innovation Incentives

Fineline Cube Apr 15, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty

Fineline Cube Apr 16, 2026
Company Drug

Gan & Lee Pharmaceuticals Secures NMPA Clinical Approval for GLR1062, China’s First-in-Class Gene Therapy for Wet Age-Related Macular Degeneration

Fineline Cube Apr 16, 2026
Company Medical Device

AccuMedical’s Blood Flow-Guided Stent Wins NMPA Approval for Brain Aneurysms

Fineline Cube Oct 27, 2022

AccuMedical Beijing Ltd has secured approval from China’s National Medical Products Administration (NMPA) for its...

Company Deals

InxMed and Huaota Bio Partner to Develop Novel Solid Tumor Combination Therapy

Fineline Cube Oct 27, 2022

China-based InxMed (Nanjing) Co., Ltd has entered into a strategic partnership with Shanghai Huaota Biopharmaceutical...

Company Deals

LEPU ScienTech Medical Technology Sets IPO Price Range Ahead of Hong Kong Listing

Fineline Cube Oct 27, 2022

China-based LEPU ScienTech Medical Technology (Shanghai) Co., Ltd is gearing up for an initial public...

Company

WuXi AppTec Posts Stellar Q3 2022 Results with 209% Profit Surge

Fineline Cube Oct 27, 2022

China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its Q3 2022 financial...

Company Drug

OriginCell’s CAR-T Therapy Receives FDA Orphan Drug Designation for Multiple Myeloma

Fineline Cube Oct 26, 2022

Shanghai-based tumor immunotherapy specialist OriginCell Therapeutics has announced that its investigational autologous chimeric antigen receptor...

Company

Novartis Q3 Revenues Rise 4% YOY; China Sales Expand Despite COVID Lockdowns

Fineline Cube Oct 26, 2022

Swiss pharmaceutical giant Novartis (NYSE: NVS) has reported a 4% year-on-year (YOY) increase in global...

Company Deals

ImmVira Secures Series C+ Financing to Advance Oncolytic Virus and Exosome Programs

Fineline Cube Oct 26, 2022

China-based biotech ImmVira has successfully secured its Series C+ financing, entering into agreements with a...

Company Drug

Ascentage Pharma Files for Phase Ib/II Study of Bcl-2 Inhibitor in Systemic Lupus Erythematosus

Fineline Cube Oct 26, 2022

Suzhou-based Ascentage Pharma (HKG: 6855) has announced the submission of a clinical filing with the...

Company Drug

Shanghai Henlius’ PD-1 Inhibitor Serplulimab Gains Australian Clearance for Phase III Study

Fineline Cube Oct 26, 2022

Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) has announced receiving regulatory clearance in Australia to...

Company Deals

ArieMedi Secures Series A+ Financing to Expand Precision Navigation Solutions

Fineline Cube Oct 26, 2022

ArieMedi Medical Science, a leading precision navigation solutions provider based in Beijing, has announced the...

Company Deals

ClinBrain Raises RMB 200 Million in Series C Financing to Boost Medical Big Data

Fineline Cube Oct 26, 2022

Shanghai-based ClinBrain, a leading clinical data repository (CDR) and medical big data services provider, has...

Company Drug

Covis Pharma’s COPD Therapies Show Positive Results in Phase III AVANT Trial

Fineline Cube Oct 26, 2022

Luxembourg-based Covis Pharma Group has released positive topline data from its Phase III AVANT trial,...

Company

Huadong Medicine Reports 10.4% Revenue Growth in Q3 2022

Fineline Cube Oct 26, 2022

Huadong Medicine Co., Ltd (SHE: 000963) has published its Q3 2022 financial report, revealing robust...

Company Drug

CSPC Receives CDE Approval for Generic Version of Pfizer’s Xeljanz

Fineline Cube Oct 26, 2022

China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) has announced that it has received market...

Company Deals

Giant Biogene Set for IPO on Hong Kong Stock Exchange to Raise Funds for Expansion

Fineline Cube Oct 25, 2022

China-based medical aesthetics company Giant Biogene Holding Co., Ltd (HKG: 2367) has announced plans to...

Company Deals

BIMI International Medical to Sell Off Underperforming Subsidiary Chongqing Zhuoda

Fineline Cube Oct 25, 2022

China-based BIMI International Medical Inc. (OTCMKTS: BIMI), a wholesaler of drugs and healthcare products, has...

Company Deals

Shandong Branden Medical Devices Files for IPO on STAR Board to Raise RMB 760M

Fineline Cube Oct 25, 2022

China-based Shandong Branden Medical Devices Co., Ltd has filed for an initial public offering (IPO)...

Company Deals

Gan & Lee Pharmaceuticals Plans RMB 814M Private Placement for Working Capital

Fineline Cube Oct 25, 2022

China-based Gan & Lee Pharmaceuticals (SHA: 603087) has announced plans to raise up to RMB...

Company Deals

Rongsheng Bio Set for IPO on STAR Board to Boost Vaccine R&D

Fineline Cube Oct 25, 2022

Shanghai Rongsheng Biotech Co., Ltd is preparing to conduct an initial public offering (IPO) of...

Company Drug

Daiichi Sankyo Initiates Global Phase II Study of DS7300 for Small-Cell Lung Cancer

Fineline Cube Oct 25, 2022

Japan-based Daiichi Sankyo Inc. (TYO: 4568) has announced the first patient dosing in a global...

Posts pagination

1 … 597 598 599 … 652

Recent updates

  • RemeGen Receives $650 Million Upfront from AbbVie in Landmark $5.6 Billion Bispecific Antibody Licensing Deal
  • Annoroad Gene Technology Files Hong Kong IPO Prospectus to Capitalize on China’s Molecular Diagnostics Growth
  • Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty
  • Gan & Lee Pharmaceuticals Secures NMPA Clinical Approval for GLR1062, China’s First-in-Class Gene Therapy for Wet Age-Related Macular Degeneration
  • Sino Biopharmaceutical Initiates Phase III Trial of LM-302 ADC Combined with Anti-PD-1 for CLDN18.2-Positive Gastric Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

RemeGen Receives $650 Million Upfront from AbbVie in Landmark $5.6 Billion Bispecific Antibody Licensing Deal

Company Deals

Annoroad Gene Technology Files Hong Kong IPO Prospectus to Capitalize on China’s Molecular Diagnostics Growth

Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty

Company Drug

Gan & Lee Pharmaceuticals Secures NMPA Clinical Approval for GLR1062, China’s First-in-Class Gene Therapy for Wet Age-Related Macular Degeneration

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.